newsfilter
← Latest News
ACCESS Newswire·

Lexaria Announces Ambitious New Hypertension Study HYPER-H21-4

DehydraTECH-CBD also being evaluated in three other human clinical studies Positive studies would support Lexaria's regulatory approval plans KELOWNA, BC / ACCESSWIRE / November 3, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Com